How to Get Tresiba in Utah: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Physicians Prescribe It

Tresiba is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, which allows once-daily dosing with a flexible injection window of up to 8 hours from the usual time [1]. Its flat, peakless pharmacokinetic profile reduces nocturnal hypoglycemia compared to older basal insulins. The SWITCH 2 trial (N=721, type 2 diabetes) demonstrated a 36% lower rate of nocturnal hypoglycemia with insulin degludec versus insulin glargine U-100 during the maintenance period [2].

Insulin degludec forms soluble multi-hexamer chains after subcutaneous injection, then dissociates slowly and predictably into active monomers [3]. This mechanism underpins the low day-to-day variability that distinguishes it from insulin glargine and insulin detemir. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and later expanded the label to include pediatric patients aged 1 year and older [4].

The American Diabetes Association 2024 Standards of Care state that "ultra-long-acting insulin analogs (degludec, glargine U-300) may be preferred in patients who experience recurrent hypoglycemia on other basal insulins" [5]. For Utah patients whose glucose control is unstable on NPH or insulin glargine U-100, switching to Tresiba under telehealth supervision is a clinically grounded option.

How to Get a Tresiba Prescription in Utah

Any Utah-licensed MD, DO, nurse practitioner with prescriptive authority, or physician assistant can write a Tresiba prescription. Telehealth platforms operating under Utah Code Ann. Section 26-60-101 (Utah Telehealth Act) may issue new prescriptions for insulin after a clinically adequate synchronous or asynchronous visit [6]. A physical examination is not legally required for insulin prescribing via telehealth in Utah, though most platforms conduct a structured intake review.

The typical telehealth pathway takes four steps. First, complete an online intake covering diabetes type, current medications, recent A1C, and any hypoglycemia history. Second, the clinician reviews your records and, if appropriate, sends a Tresiba prescription to your preferred pharmacy. Third, you fill the prescription at a retail pharmacy in Utah or through a mail-order pharmacy licensed in the state. Fourth, the platform schedules a follow-up at 4 to 6 weeks to review fasting glucose logs and adjust the dose.

Utah-based telehealth providers prescribing insulin include both diabetes-specialist platforms and general primary care services. HealthRX connects Utah patients with board-certified endocrinologists and internists who can evaluate basal insulin candidacy, order labs, and send a prescription on the same day as the visit in most cases.

Labs Required Before Starting Tresiba in Utah

A Tresiba prescription does not require an extensive lab panel, but a responsible prescriber will want specific data before finalizing the dose. Hemoglobin A1C is the single most useful baseline value. The ADA recommends an A1C target of <7.0% for most non-pregnant adults with diabetes and <8.0% for those with significant hypoglycemia unawareness or limited life expectancy [5]. Starting Tresiba without a recent A1C (within 90 days) is generally considered substandard care.

A basic metabolic panel (BMP) covering serum creatinine, eGFR, sodium, and potassium is standard. Insulin degludec does not require dose adjustment for renal impairment per the FDA label, but knowing the eGFR guides concomitant medication management [4]. A fasting glucose or 2-week self-monitored glucose log helps the prescriber set the initial unit count. For type 1 patients, a C-peptide and anti-GAD antibody panel helps confirm the diagnosis if there is any clinical ambiguity [7].

The Endocrine Society Clinical Practice Guideline on diabetes management notes that baseline thyroid-stimulating hormone (TSH) testing is appropriate for type 1 patients because autoimmune thyroid disease co-occurs in approximately 17 to 30% of that population [8]. Utah telehealth platforms typically order labs through Quest Diagnostics or ARUP Laboratories (headquartered in Salt Lake City), with results available in 1 to 3 business days.

Cardiovascular Safety: The DEVOTE Trial

Cardiovascular safety is a mandatory consideration for any basal insulin. The FDA now requires dedicated cardiovascular outcomes trials (CVOTs) for new diabetes drugs. DEVOTE (N=7,637 adults with type 2 diabetes at high cardiovascular risk, median follow-up 2.0 years) compared insulin degludec to insulin glargine U-100 in a double-blind, treat-to-target design [9]. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

Insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority) [9]. DEVOTE also reported that the rate of severe hypoglycemia was 27% lower with insulin degludec than with insulin glargine U-100 (1.48 vs. 2.19 episodes per patient-year of exposure), a clinically meaningful secondary finding [9]. For Utah patients with established cardiovascular disease or multiple risk factors, this safety profile supports choosing Tresiba over older basal agents.

The SWITCH 1 trial (N=501, type 1 diabetes) similarly showed a 35% reduction in nocturnal confirmed hypoglycemia with insulin degludec versus insulin glargine U-100 during the maintenance phase [10]. These data apply directly to Utah type 1 patients for whom nocturnal hypoglycemia has been a barrier to tighter glucose control.

Prior Authorization in Utah: What Documentation You Need

Most commercial insurers in Utah require prior authorization (PA) for Tresiba because it is a branded, non-generic insulin. Utah's Medicaid program (Healthy Utah) does not cover Tresiba as of mid-2025, so PA applies only to commercial plans. The standard documentation package includes five items.

First, the prescriber's clinical notes documenting the diabetes diagnosis (type 1 or type 2) with ICD-10 code E10 or E11. Second, a recent A1C result. Third, documentation of an adequate trial (usually 60 to 90 days) on at least one preferred formulary basal insulin such as insulin glargine (Basaglar, Lantus, Semglee) or insulin detemir (Levemir). Fourth, evidence of suboptimal response defined as persistent A1C above goal, recurrent hypoglycemia, or unacceptable glycemic variability on the formulary agent. Fifth, any physician attestation letter if the patient has a documented contraindication or intolerance to preferred agents [11].

Telehealth providers can compile and submit this PA package electronically. Turnaround from commercial Utah insurers typically runs 3 to 10 business days for standard review or 24 to 72 hours for urgent review. If the PA is denied, the prescriber can submit a peer-to-peer review request, which succeeds at a higher rate when the clinical rationale references the DEVOTE and SWITCH trial data [9][10].

Tresiba Pricing and Savings Options in Utah

Without insurance, Tresiba FlexTouch pens (3 mL, 100 units/mL or 200 units/mL) cost approximately $350 to $500 per pen at Utah retail pharmacies. A typical type 2 patient using 30 units per day consumes one 3 mL/100-unit pen per 10 days, making the annual out-of-pocket cost prohibitive without assistance [4].

Novo Nordisk's Insulins Valyou Savings Program caps the monthly cost of Tresiba at $99 for eligible uninsured or underinsured patients [12]. Patients with commercial insurance can use the Tresiba savings card to reduce copays to as low as $10 per month, subject to program eligibility. Income-qualified patients may also apply to the Novo Nordisk Patient Assistance Program (PAP), which provides Tresiba at no cost to those who meet federal poverty level thresholds [12].

Utah retail pharmacy chains stocking Tresiba routinely include Smith's (Kroger), Harmons, Costco, and most independent pharmacies. GoodRx and similar discount programs typically offer 20 to 35% reductions off the retail price, though these discounts cannot be combined with manufacturer coupons. Mail-order options through CVS Caremark, Express Scripts, and OptumRx ship to all Utah zip codes, including rural areas in San Juan, Garfield, and Daggett counties where local pharmacy access may be limited [13].

503A Compounding Pharmacies in Utah and Insulin Degludec

Utah-licensed 503A compounding pharmacies may prepare patient-specific formulations of insulin degludec, provided a valid prescription exists and the preparation meets USP <797> sterile compounding standards [14]. 503A pharmacies compound for individual patients rather than in bulk (that is the domain of 503B outsourcing facilities). A physician or authorized prescriber must send a prescription directly to the compounding pharmacy specifying the concentration, volume, and any excipients.

Compounded insulin degludec is not FDA-approved and differs legally from the brand-name Tresiba product. The FDA has not placed insulin degludec on its list of drugs that may be compounded (the 503B bulk drug substances list), meaning 503B outsourcing facilities cannot legally produce it in bulk for office stock [15]. 503A pharmacies in Utah, however, operate under a separate legal framework and may compound insulin degludec for individually identified patients when a prescriber determines a commercial product is unsuitable, for example, due to concentration requirements or allergy to a commercial excipient.

Patients considering 503A compounded insulin degludec should confirm the pharmacy holds a current Utah Division of Occupational and Professional Licensing (DOPL) pharmacy license and follows USP <797> guidelines for sterile preparations [14].

Telehealth Prescribing of Tresiba in Utah: Legal Framework

Utah's Telehealth Act (Utah Code Ann. Section 26-60-101 et seq.) defines a valid patient-provider relationship and authorizes prescribing after a clinically appropriate evaluation conducted via synchronous audio-video, asynchronous store-and-forward, or a hybrid model [6]. Insulin is not a controlled substance, so the federal Ryan Haight Act (which restricts Schedule II-V prescribing via telehealth) does not apply [16]. A Utah-licensed prescriber may therefore issue a new Tresiba prescription following a telehealth-only encounter without requiring an in-person visit.

The Utah Division of Professional Licensing specifies that nurse practitioners who hold a collaborative practice agreement (CPA) with a Utah-licensed physician have full prescriptive authority, including for insulin and other non-controlled medications [17]. Physician assistants licensed in Utah may also prescribe insulin under a supervising physician's delegation agreement. This means the pool of Utah telehealth providers who can legally write Tresiba prescriptions is broad.

The practical implication for rural Utah patients is significant. Roughly 23% of Utah's population lives in rural or frontier counties where endocrinology care is unavailable within 60 miles [18]. Telehealth access removes that geographic barrier for basal insulin management without compromising the standard of care.

Transferring an Existing Tresiba Prescription to Utah

Patients relocating to Utah from another state may transfer a Tresiba prescription to a Utah pharmacy under specific conditions. Utah follows the National Association of Boards of Pharmacy (NABP) model that permits a one-time transfer of a non-controlled prescription between pharmacies in different states, provided the receiving Utah pharmacy contacts the originating pharmacy directly and the original prescription has remaining refills [19].

If the out-of-state prescription has no remaining refills, the patient needs a new prescription from a Utah-licensed provider. A telehealth visit is the fastest way to obtain one. Bring the original prescription bottle, your most recent A1C result, and your current Tresiba dose (units per day) to the telehealth encounter. The prescriber can issue a new Utah prescription the same day in most cases.

Patients whose out-of-state prescriber is licensed in multiple states including Utah present a simpler scenario. That prescriber may continue to send Tresiba prescriptions to Utah pharmacies as long as the prescription complies with Utah's format requirements, including the prescriber's Utah DEA number for controlled substances (not required for insulin) and the pharmacy's Utah license number [19].

Dosing Insulin Degludec: Starting Points and Titration

The FDA-approved starting dose for insulin-naive type 2 patients is 10 units once daily [4]. For patients switching from another basal insulin, the conversion is unit-to-unit (1:1) from insulin glargine U-100 or insulin detemir, with a possible 20% dose reduction recommended when switching from insulin glargine U-300 to avoid hypoglycemia [4].

Titration follows a treat-to-target protocol. The most studied approach, used in DEVOTE and multiple phase 3 trials, targets a fasting self-monitored plasma glucose of 71 to 90 mg/dL (3.9 to 5.0 mmol/L) [9]. Dose adjustments of 2 units every 3 days are standard when fasting glucose exceeds 90 mg/dL on at least 3 consecutive measurements. The titration algorithm published by Philis-Tsimikas et al. showed that patient-led titration using this rule achieved A1C reductions equivalent to clinician-led titration in a primary care setting [20].

For type 1 patients, the basal dose typically covers 30 to 50% of total daily insulin requirements, with the remainder administered as prandial insulin (rapid-acting or ultra-rapid-acting analog) [5]. Utah telehealth providers adjust this ratio based on patient-reported carbohydrate intake, activity level, and continuous glucose monitor (CGM) data when available.

Monitoring After Starting Tresiba in Utah

After initiating Tresiba, a follow-up A1C at 3 months is the standard benchmark [5]. Fasting glucose logs (or CGM time-in-range data) provide earlier signal. A time-in-range target of >70% between 70 and 180 mg/dL is endorsed by the ADA for most patients using CGM [5]. The FDA label recommends periodic monitoring of renal function and potassium in patients on concurrent diuretics or ACE inhibitors because hypoglycemia-related counter-regulatory responses can affect electrolyte balance [4].

Utah telehealth platforms typically schedule three touchpoints in the first 90 days: an initial prescription visit, a 4-week check-in (glucose log review and dose titration), and a 90-day A1C review. After stabilization, a twice-yearly A1C cadence is appropriate for most patients per ADA Standards [5]. ARUP Laboratories in Salt Lake City offers same-day A1C processing for most Utah zip codes, with results available to the telehealth prescriber within 24 hours via electronic health record integration [21].